Equilibration rate constant, k
Effect-site concentration is widely used to determine drug dosage in anesthesia practice. To obtain effect-site concentration, a pharmacokinetic model with a corresponding equilibration rate constant ...
Benzodiazépines : Questions médicales fréquentes
Sous-catégories
24 au total
└─
Alprazolam
AlprazolamD000525 -
D03.633.100.079.080.030
└─
Benzodiazépinones
BenzodiazepinonesD001570 -
D03.633.100.079.080.070
└─
Chlordiazépoxyde
ChlordiazepoxideD002707 -
D03.633.100.079.080.150
└─
Clobazam
ClobazamD000078306 -
D03.633.100.079.080.165
└─
Clorazépate dipotassique
Clorazepate DipotassiumD003009 -
D03.633.100.079.080.180
└─
Estazolam
EstazolamD004949 -
D03.633.100.079.080.250
└─
Médazépam
MedazepamD008472 -
D03.633.100.079.080.550
└─
Midazolam
MidazolamD008874 -
D03.633.100.079.080.575
└─
Olanzapine
OlanzapineD000077152 -
D03.633.100.079.080.738
└─
Triazolam
TriazolamD014229 -
D03.633.100.079.080.900
└─└─
Bromazépam
BromazepamD001960 -
D03.633.100.079.080.070.110
└─└─
Clonazépam
ClonazepamD002998 -
D03.633.100.079.080.070.150
└─└─
Dévazépide
DevazepideD020109 -
D03.633.100.079.080.070.200
└─└─
Diazépam
DiazepamD003975 -
D03.633.100.079.080.070.216
└─└─
Flumazénil
FlumazenilD005442 -
D03.633.100.079.080.070.305
└─└─
Flunitrazépam
FlunitrazepamD005445 -
D03.633.100.079.080.070.320
└─└─
Flurazépam
FlurazepamD005479 -
D03.633.100.079.080.070.348
└─└─
Lorazépam
LorazepamD008140 -
D03.633.100.079.080.070.450
└─└─
Nitrazépam
NitrazepamD009567 -
D03.633.100.079.080.070.565
└─└─
Oxazépam
OxazepamD010076 -
D03.633.100.079.080.070.663
└─└─
Pirenzépine
PirenzepineD010890 -
D03.633.100.079.080.070.750
└─└─
Prazépam
PrazepamD011222 -
D03.633.100.079.080.070.784
└─└─
Témazépam
TemazepamD013693 -
D03.633.100.079.080.070.880
└─└─└─
Nordazépam
NordazepamD003708 -
D03.633.100.079.080.070.216.500
Sources (937 au total)
Insights into the molecular mechanism of triazolopyrimidinone derivatives effects on the modulation of α
Due to the importance of benzodiazepine drugs in clinical practice, such as the treatment of anxiety disorders, depression, and insomnia and the side effects of classical benzodiazepines, the study of...
Identifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection.
Methadone and buprenorphine have pharmacologic properties that are concerning for a high risk of drug-drug interactions (DDIs). We performed high-throughput screening for clinically relevant DDIs with...
A descriptive analysis of pharmacological management of aggression and/or agitation in patients with traumatic brain injury in a Southwest Virginia inpatient population.
Traumatic brain injury (TBI) is a major cause of disability, and it has been associated with agitation and aggression. In a previous study, we reviewed the literature to identify evidence-based pharma... Adult patients who were admitted to Carilion Clinic's inpatient facilities from March 30, 2013, to March 30, 2018, had a diagnosis of TBI, and received psychiatric consultation for agitation and/or ag... About 68% of patients were started on benzodiazepines and/or typical antipsychotics and 23% of patients were subsequently discharged on these medication categories. Only 23% of patients were ordered t... This study demonstrates the widespread use of typical antipsychotics and benzodiazepines in the management of agitation in TBI and the importance of multidisciplinary collaboration, research and educa...
Correlates of Opioid Use Among Ontario Long-Term Care Residents and Variation by Pain Frequency and Intensity: A Cross-sectional Analysis.
Chronic non-cancer pain is common among older residents of long-term care (LTC) homes and often poorly recognized and treated. With heightened concerns regarding opioid prescribing in recent years, it... The aims were to estimate the prevalence and correlates of opioid use among non-palliative LTC residents and explore variation in opioid prevalence and correlates across strata defined by pain frequen... We conducted a population-based cross-sectional study of all older (aged > 65 years) LTC residents (excluding those with cancer or receiving palliative care) in Ontario, Canada during 2018-2019. Healt... Among 75,020 eligible residents (mean age 85.1 years; 70% female), the prevalence of opioid use was 18.5% and pain was 29.4%. Opioid use ranged from 12.2% for residents with no current pain to 55.7% f... Our findings describe resident sub-groups at potentially higher risk of adverse health outcomes in relation to both opioid use and non-use. LTC clinical and policy changes informed by research are req...
Use of pharmacological treatment for posttraumatic stress disorder: Analysis of a psychiatric population in Switzerland and comparison with international guidelines.
Several international guidelines for the pharmacological treatment of posttraumatic stress disorder (PTSD) have been published. However, it is unclear whether clinicians use these procedures in their ... Retrospective chart review study between 2005 and 2015 of adult patients with PTSD and no other documented psychiatric comorbidity.... Fifty-two outpatients and 21 inpatients were included; 47% had at least one psychopharmacological treatment at admission. Among them, 47% had one or several antidepressants, mainly escitalopram (31%, ... Clinicians in this study frequently prescribed antidepressants to treat PTSD, as recommended. However, most of the antidepressants used were not recommended in the VA/DoD guidelines. Benzodiazepines a...
Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England.
Synthetic cannabinoid receptor agonists (SCRA) are commonly encountered new psychoactive substances. Here we report the recent detection of ADB-BUTINACA in samples from patients attending United Kingd... Consenting adults (≥16 y) presenting to participating hospitals with toxicity after suspected drug misuse have been included in the Identification Of Novel psychoActive substances (IONA) study since M... By December 2021, analytical data were available for 1279 IONA participants and ADB-BUTINACA was detected in at least one sample from 10 (9 males, age range 16-51 median 45 years), all presenting sinc... ADB-BUTINACA has recently emerged as a drug of misuse in England. Clinical features of toxicity are consistent with those of other SCRA and include reduced level of consciousness, respiratory and/or m...
Alprazolam-related deaths in Scotland, 2004-2020.
The benzodiazepine drug alprazolam, a fast-acting tranquiliser, cannot be prescribed on the National Health Service in the United Kingdom. Illicit alprazolam supply and consumption have increased. Con... Statistics on deaths where alprazolam was mentioned in the 'cause of death' were obtained from official mortality registers. Anonymised Scottish case-level data were obtained. Data were examined in re... Scotland registered 370 deaths in 2004-2020; 366 of these occurred in 2015-2020: most involved males (77.1%); mean age 39.0 (SD 12.6) years. The principal underlying cause of death was accidental pois... Alprazolam-related deaths are likely due to an increasing illicit supply. The fall in deaths in 2019-2020 is partially due to increased use of designer benzodiazepines. Treatment for alprazolam depend... More awareness of alprazolam contributing to deaths, especially in conjunction with other CNS depressants, is needed by consumers and clinicians. Improved monitoring of illicit supplies could identify...
Effect of Different Interventions to Help Primary Care Clinicians Avoid Unsafe Opioid Prescribing in Opioid-Naive Patients With Acute Noncancer Pain: A Cluster Randomized Clinical Trial.
Prescription opioids can treat acute pain in primary care but have potential for unsafe use and progression to prolonged opioid prescribing.... To compare clinician-facing interventions to prevent unsafe opioid prescribing in opioid-naive primary care patients with acute noncancer pain.... We conducted a multisite, cluster-randomized, 2 × 2 factorial, clinical trial in 3 health care systems that comprised 48 primary care practices and 525 participating clinicians from September 2018 thr... Practices randomized to: (1) control; (2) opioid justification; (3) monthly clinician comparison emails; or (4) opioid justification and clinician comparison. All groups received opioid prescribing gu... Primary outcome measures were receipt of an initial opioid prescription at the qualifying clinic visit. Other outcomes were opioid prescribing for more than 3 months and a concurrent opioid/benzodiaze... Among 22 616 enrolled patient participants (9740 women [43.1%]; 64 American Indian/Alaska Native [0.3%]; 590 Asian [2.6%], 1120 Black/African American [5.0%], 1777 Hispanic [7.9%], 225 Native Hawaiian... In this cluster randomized clinical trial, comparison emails decreased the proportion of opioid-naive patients with acute noncancer pain who received an opioid prescription, progressed to treatment wi... ClinicalTrials.gov Identifier: NCT03537573....
Total intravenous anesthesia induced and maintained by a combination of remimazolam and remifentanil without a neuromuscular blocking agent: a prospective, observational pilot study.
A novel short-acting benzodiazepine, Remimazolam, has recently been approved for general anesthesia and sedation. Hence, we investigated the feasibility and safety of remimazolam during the induction ... This prospective observational study included 38 patients undergoing hysteroscopic surgery. Remimazolam and remifentanil were the main anesthetic agents without an NMBA, and a supraglottic airway was ... General anesthesia was successfully administered to 37 patients using remimazolam and remifentanil without NMBA. The induction doses of remimazolam and remifentanil were 0.4 mg/kg (interquartile range... Remimazolam can be combined with remifentanil without an NMBA in female patients who undergo hysteroscopic surgery, during which a supraglottic airway is a feasible method to protect the airway.... The study protocol was registered at ClinicalTrials.gov (NCT05025410) on 27/08/2021....